LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
Rhea-AI Summary
LENZ Therapeutics (Nasdaq: LENZ) reported preliminary unaudited results for Q4 2025 and recent corporate updates following the October 2025 launch of VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia.
Key highlights: first commercial sales in October 2025, broad retail and ePharmacy availability by mid‑November 2025, approximately $1.6 million in net product revenue in Q4 2025, over 20,000 prescriptions filled through Q4, and >6,500 unique prescribing eye care professionals with >55% prescribing multiple times in Q4. In January 2026 LENZ signed an exclusive Middle East commercialization partnership with Lunatus including upfront, milestone payments and a revenue share.
Positive
- First commercial sales of VIZZ in October 2025
- Q4 2025 net product revenue of approximately $1.6 million
- Over 20,000 prescriptions filled through Q4 2025
- More than 6,500 unique prescribing ECPs; >55% multiple prescriptions
- Exclusive Middle East commercialization agreement with Lunatus
Negative
- Revenue limited to approximately $1.6 million in launch quarter
- Commercial availability achieved only by mid‑November 2025
- Monetization outside US depends on partnership terms and milestones
News Market Reaction
On the day this news was published, LENZ declined 3.20%, reflecting a moderate negative market reaction. Argus tracked a trough of -12.3% from its starting point during tracking. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $17M from the company's valuation, bringing the market cap to $510M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LENZ gained 2.25% while key biotech peers were mixed to positive: AMLX +4.72%, DNTH +4.18%, ELVN +2.18%, TRVI +6.31%, TRML 0%. No broad, synchronized sector move is indicated.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Regional partnership | Positive | +3.0% | Exclusive Middle East commercialization deal with milestone and revenue sharing. |
| Dec 01 | Regulatory filing | Positive | -0.4% | South Korea NDA submission for VIZZ based on positive Phase 3 data. |
| Nov 25 | Investor conferences | Neutral | +2.8% | Announcements of multiple December investor conference presentations. |
| Nov 05 | Quarterly earnings | Neutral | -23.5% | Q3 2025 results with FDA approval and initial launch plus higher expenses. |
| Oct 29 | Earnings scheduling | Neutral | -0.6% | Announcement of timing and access details for Q3 2025 call. |
Earnings and partnership updates have produced mixed reactions, with some positive commercial milestones coinciding with sharp declines.
Over the last several months, LENZ has transitioned from preparing for approval of VIZZ to actively commercializing it. Key milestones included multiple licensing and partnership deals, international NDA submissions, and the October 2025 U.S. launch. Past earnings-related updates around this commercialization shift have triggered both gains and steep pullbacks (e.g., -23.46% after Q3 2025 results). Today’s preliminary Q4 2025 launch metrics and the additional Middle East partnership continue this commercialization narrative, adding early revenue and prescription data to prior cash and licensing disclosures.
Market Pulse Summary
This announcement provides preliminary Q4 2025 launch metrics for VIZZ, including net product revenue of $1.6 million, over 20,000 prescriptions, and more than 6,500 unique prescribers, plus a new Middle East commercialization partnership. In the past, earnings updates have led to sizable moves, both positive and negative. Investors may focus on prescription growth, prescriber repeat rates, regional deal execution, and future earnings reports to gauge the durability of this early commercial momentum and associated spending levels.
Key Terms
aceclidine ophthalmic solution medical
presbyopia medical
AI-generated analysis. Not financial advice.
Launched VIZZ™ (aceclidine ophthalmic solution)
Achieved approximately
Over 6,500 unique ECPs prescribed VIZZ; more than
SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmic solution)
“We are proud of the strong execution delivered in our first quarter of launch, as the team established a solid foundation of awareness, confidence, and willingness to prescribe VIZZ across the eye care professional community,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “More than 6,500 eye care professionals have already written a prescription for VIZZ, the majority of whom prescribed multiple times, signaling early confidence in VIZZ as a convenient and effective alternative to reading glasses. At the same time, over 20,000 prescriptions were filled during our first quarter of launch, exceeding our expectations and reinforcing the early momentum behind VIZZ. Building on this progress, and together with our campaign spokesperson Sarah Jessica Parker, we look forward to launching the VIZZ DTC campaign this quarter.”
Fourth Quarter 2025 Commercial Highlights
- First commercial product sale of VIZZ in October 2025, the first and only aceclidine-based eye drop for the treatment of presbyopia
- Full multi-channel access established through epharmacy and substantially all retail pharmacies by mid-November 2025
- VIZZ net product revenue of approximately
$1.6 million in Q4 2025 - Over 20,000 prescriptions filled through Q4 2025
- Rapid uptake by prescribing ECPs with over 6,500 unique prescribing ECPs; more than
55% prescribed multiple times in Q4 2025
Additional Recent Corporate Updates
- In January 2026, the Company announced an exclusive commercialization partnership for VIZZ with Lunatus in the Middle East. Under the terms of the agreement, LENZ will receive upfront, regulatory and commercial milestone payments, in addition to a significant share of revenue generated in the region through a pre-determined minimum product supply price. This agreement represents the fourth commercialization partnership for VIZZ outside the United States.
About LENZ Therapeutics
LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZTM (aceclidine ophthalmic solution)
About Presbyopia
Presbyopia is the inevitable loss of near vision associated with aging, impacting the daily lives of nearly all people over the age of 45. As people age, the crystalline lens in their eyes gradually hardens and becomes less able to change shape. This loss of elasticity of the lens reduces the ability of the lens to focus incoming light from near objects onto the retina. Adults over 50 years of age lose, on average, 1.5 lines of near vision every six years. Although the progression of presbyopia is gradual, presbyopes often experience an abrupt change in their daily life as the symptoms become more pronounced starting in their mid-40s, when reading glasses or other corrective aids are suddenly necessary to read text or conduct close-up work. Presbyopia is typically self-diagnosed and self-managed with over-the-counter reading glasses, or managed, after evaluation by an ECP, with prescription reading or bifocal glasses or multifocal contact lenses.
About VIZZ (aceclidine ophthalmic solution)
VIZZ (aceclidine ophthalmic solution)
VIZZ Indication and Important Safety Information
INDICATION
VIZZ (aceclidine ophthalmic solution)
IMPORTANT SAFETY INFORMATION
- Do not use VIZZ if allergic to any of the ingredients.
- To help avoid potential eye injury or contamination of the product, do not allow the vial tip to touch the eye or any surfaces. Discard the opened vial immediately after use.
- Contact lenses should be removed before using VIZZ. After dosing, contact lenses can be reinserted after 10 minutes.
- If using more than one topical eye medication, the medicines should be administered at least 5 minutes apart.
- Temporary dim or dark vision may be experienced after using VIZZ. Do not drive or operate machinery if vision is not clear.
- Seek immediate medical care if sudden onset of flashing lights, floaters, or vision loss is experienced.
ADVERSE REACTIONS
The most common reported adverse reactions of participants were instillation site irritation (
For additional information, please see the full Prescribing Information available at www.VIZZ.com/full-prescribing-information.pdf.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. You can identify forward-looking statements by words such as “may,” “will,” “could,” “can,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “poised,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, but not all forward-looking statements will contain these words. ” Forward-looking statements in this press release include statements regarding the timing and availability of VIZZ, including the VIZZ DTC campaign; potential market size for VIZZ; its ability to meet patient needs and become standard of care; LENZ commercialization plans, including international partnering plans, and the quotations of LENZ management. These statements are based on numerous assumptions concerning VIZZ, target markets and involve substantial risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievement to be materially different from the information expressed or implied by these forward-looking statements, including those risk factors described in the section titled “Risk Factors” in our Quarterly Report on Form 10-Q filed for the quarter ended September 30, 2025 and our subsequent filings with the SEC. The unaudited results in this press release, including Q4 2025 net product revenue, are preliminary and subject to the completion of accounting and annual audit procedures and are therefore subject to adjustment. We cannot assure you that the forward-looking statements in this press release or the assumptions upon which they are based will prove to be accurate. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, LENZ disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Contact:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
FAQ
When did LENZ (NASDAQ: LENZ) first commercialize VIZZ and become broadly available?
How much net product revenue did LENZ report for VIZZ in Q4 2025?
How many VIZZ prescriptions were filled through Q4 2025 and how many prescribers used it?
What partnership did LENZ announce for VIZZ in January 2026?
What early adoption signal did LENZ cite for VIZZ among eye care professionals in Q4 2025?
